A British Society for Immunology event
The BSI Tumour Immunology Group are excited to celebrate the relaunch of this Affinity Group with an inaugural high quality one-day meeting on Thursday 19th March 2020 at Austin Court Birmingham.
Immune checkpoint blockade has been making headlines for several years, transforming therapy for a range of previously untreatable advanced cancers. However, although some factors linked with improved responses are known, our understanding of the science underlying this approach is emphatically incomplete, and many patients do not respond to therapy, or experience serious side effects. The BSI Tumour Immunology Group have worked hard to put together a strong programme, focussing on exploring the fascinating and diverse immune axes that link with the checkpoint blockade concept.
In addition to providing a brief clinical perspective on current checkpoint blockade therapy, the range of speakers will explore the fundamental receptor-ligand systems involved in checkpoint blockade, key cellular subsets and regulatory axes, how the tumour and its microenvironment influence checkpoint blockade, followed by novel therapy developments in the checkpoint blockade area, including combination approaches and neoantigen reactive T cell therapy. The day will end with a networking session to bring together attendees from all stages of the therapeutic pathway, from basic scientists to translational clinicians and industry partners.
The abstract submission deadline is Thursday 20th February 2020.
Further details and booking
For further information and to book this event, please visit the BSI event website